C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. - Wikidata - wikimedia - TriplyDB

C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.

C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.

http://www.wikidata.org/entity/Q34003454

about

Lone atrial fibrillation: where are we now?Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes.Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study Cardiac rehabilitation in patients with ST-segment elevation myocardial infarction: can its failure be predicted?The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage Biomarkers in acute myocardial infarction.Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk Risk stratification in emergency patients by copeptin Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage.Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.Hyponatremia and anti-diuretic hormone in Legionnaires' disease.Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospital.Copeptin is an independent predictor of diabetic heart disease and death.Copeptin testing in acute myocardial infarction: ready for routine use?Copeptin and risk stratification in patients with acute dyspnea.Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction.Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration.Increased Serum Sodium and Serum Osmolarity Are Independent Risk Factors for Developing Chronic Kidney Disease; 5 Year Cohort Study.Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.Copeptin: a new and promising diagnostic and prognostic marker Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome.Plasma copeptin levels are inversely associated with intima-media-thickness in men: the population-based KORA F4 study.Relationship Between Water Intake and Metabolic/Heart Diseases: Based on Korean National Health and Nutrition Examination Survey The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial COPeptin for diagnosis and prediction in Acute Coronary Syndrome (COPACS) Study: design and objectives.Copeptin and its potential role in diagnosis and prognosis of various diseases.Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome.Proteomic biomarkers for diagnosis in acute myocardial infarction.Established and novel biomarkers in ST-elevation myocardial infarction.Novel biomarkers in chronic heart failure.Biomarkers in community-acquired pneumonia.Potential blood biomarkers for stroke.Experimental biomarkers in heart failure: an update.Therapeutic implications of biomarkers in chronic heart failure.Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs.Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers.Determinants of survival following hospitalization for acute heart failure.

P2860

Q30409016-451323FC-0E63-438C-ABE5-791DBD12E266 Q30434636-4CDB94CE-78A5-47E0-8955-07A146B03202 Q31131029-913069B2-7E65-4201-8548-CE1CB05385FC Q33442196-E66B506E-580D-48A9-97D5-9B21B0258D0E Q33526184-649E1674-DBDA-4576-B1DC-869513FE1D04 Q33588084-C7FB155F-44BC-4FAD-9C3F-61BC4E761AB5 Q33596823-C6F0984D-7DF1-4F96-BCA1-486FDDAC909F Q33721171-FDB7B69D-4988-499F-9D42-76871D16D1B4 Q33740059-2A4278C1-AB20-4FE4-A663-759DDD753C04 Q33932812-B7D97907-FD6A-4FD6-8877-F0827C59E440 Q34134378-9E16D921-530A-4D01-804C-589F622C9E21 Q34551235-F807BD17-57A8-4A4D-96D0-96A928B12E54 Q34726918-3CF9B492-6366-47FF-B8E0-CD5BDC70C521 Q35065229-4930E6AB-B326-46B4-B733-555B64E88BB8 Q35193926-39CE7405-D9BE-4684-A88E-2389110C8B01 Q35433105-38841421-31E0-420F-B5F5-E8477E058FB2 Q35556651-9AB92E6F-067E-4315-8C13-490E3B0C1853 Q35561316-1A7872D5-D864-45BB-A9E1-2AE7B709F965 Q35569452-A277443D-165A-40C1-BB0C-B6681C2D8D17 Q35908323-A6495A64-2AD2-46DD-91CA-181F49EC01D4 Q36247486-F9FB961D-D163-48C4-9897-609DC8CF4A97 Q36329310-F94BE865-40B3-4B77-A000-02CBBF45D873 Q36748907-77F31DA4-BAF1-4ED7-AB06-13F926E52DBD Q37257539-8245E96E-FCB9-4F61-8BCA-6901E6E877A0 Q37306950-F9DE3720-8872-4D6E-A040-C45D82D8F8D7 Q37364802-AF875828-E92C-4AE2-86EE-303119BA8F3A Q37448445-466DA946-7211-4F15-BE46-7947CCC908E2 Q37463800-EA464C40-F445-47BA-BC1F-B83868C73CF9 Q37508425-4033944F-781E-4855-96B0-EB52A367B381 Q37716537-A1436141-241F-40AA-BF00-5084E3C1C438 Q37798014-2818A690-0F32-46E2-9B19-8540AFE0D4F4 Q37907327-B054065B-05FF-44FA-8523-4C23A8CB1414 Q37997237-82B4B192-1088-408D-908E-71F1C7D6C70C Q37997820-F9CF1166-C92C-4CCC-8AAC-1B57EC2C7572 Q38042459-A2807D35-358B-4771-9329-56068FD7D887 Q38055505-29ED7AC7-3A07-45C0-B154-22BF351996B9 Q38121720-468F8F89-B9D4-45EC-9C9E-ADCE94215A7D Q38136336-299F79A5-0A57-477E-927F-AD3C690AD29B Q38177341-9931C3CD-ED36-428E-BB63-7D5280E51F18 Q38183318-CAFD320E-66C6-4AE3-8429-7B8314AF68D7

P2860

C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.

http://www.wikidata.org/entity/Q34003454

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@ast

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@en

C-terminal provasopressin

@nl

type

label

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@ast

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@en

C-terminal provasopressin

@nl

prefLabel

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@ast

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@en

C-terminal provasopressin

@nl

P1433

Q34003454-2E549BA9-199D-4ED5-9F23-D1944C01214D

P1476

Q34003454-A17F8040-48E5-412F-BD6C-63E1E00811B4

P2093

Q34003454-300F6448-AC11-463D-9D4F-6CE7DA3CE6F7

Q34003454-506E22BA-CE6C-49CD-B253-D67269F788D8

Q34003454-549E8556-5678-4BFB-974E-B459F7B695B9

Q34003454-7A11A68D-50CF-4E9A-AF40-A3738494AB59

Q34003454-81A44F21-E298-40D4-8A1C-655EBBB621E8

Q34003454-B456AB26-5467-41ED-B11B-40DEB161442E

Q34003454-C6C9F9C1-BEC6-4AFB-AAAF-C005A5DE5AC9

Q34003454-E0B885E2-F782-4999-BEB7-2522F798478B

Q34003454-FFF46A11-BB63-4E92-BD15-CD158F75DECB

P304

Q34003454-E461F7C9-9028-43CF-8EDA-F5464742BB13

P31

Q34003454-1DDF639A-ED25-444B-A7A8-0F41EAC423C3

P356

Q34003454-22CEC35F-A4B1-4E61-8317-954A0919604C

P407

Q34003454-317A9DCE-B455-4EE1-B183-54F20779C1E1

P433

Q34003454-61D7D819-DE69-448A-8EC9-F6BFCB9B501D

P478

Q34003454-FAD8789D-5F31-46C5-9CAA-11A49BEE013A

P50

Q34003454-D5BEBC8B-D3CF-4160-A3C1-290B87BC9608

P577

Q34003454-8BC369BA-8368-4486-A3BF-DCAFF9C22D52

P5875

Q34003454-ED1BBB74-A2E3-4C36-B5FC-A633E7945A83

P698

Q34003454-6013862C-B4A3-468B-98E5-32478F174053

P921

Q34003454-BA94A5DF-E7B5-46B2-AD49-D51311469D7A

P356

CIRCULATIONAHA.106.685503

P1433

P1476

C-terminal provasopressin (cop ...... farction Peptide (LAMP) study.

@en

P2093

Andreas Bergmann

http://www.w3.org/2001/XMLSchema#string

Iain B Squire

http://www.w3.org/2001/XMLSchema#string

Joachim Struck

http://www.w3.org/2001/XMLSchema#string

Joan E Davies

http://www.w3.org/2001/XMLSchema#string

Nils G Morgenthaler

http://www.w3.org/2001/XMLSchema#string

Onkar S Dhillon

http://www.w3.org/2001/XMLSchema#string

Paulene A Quinn

http://www.w3.org/2001/XMLSchema#string

Russell J O'Brien

http://www.w3.org/2001/XMLSchema#string

Sohail Q Khan

http://www.w3.org/2001/XMLSchema#string

P304

2103-2110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.106.685503

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6403070

http://www.w3.org/2001/XMLSchema#string

P698

17420344

http://www.w3.org/2001/XMLSchema#string

P921